Targets › IL33R
1 program from 1 company in 2 trials: 2 Phase 3; Respiratory; next expected readout Jun 2027.
Open in Phaseline: the race on IL33R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Roche | Astegolimab IL-33 receptor (ST2) inhibitor | IL1RAP, IL33R | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary Disease | Jun 2027 |
Chronic Obstructive Pulmonary Disease (COPD) (1) Chronic Obstructive Pulmonary Disease (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.